Relationship of body size and shape to the development of diabetes in the diabetes prevention program - PubMed (original) (raw)
Randomized Controlled Trial
. 2006 Nov;14(11):2107-17.
doi: 10.1038/oby.2006.246.
Affiliations
- PMID: 17135629
- PMCID: PMC2373982
- DOI: 10.1038/oby.2006.246
Randomized Controlled Trial
Relationship of body size and shape to the development of diabetes in the diabetes prevention program
Diabetes Prevention Program Research Group. Obesity (Silver Spring). 2006 Nov.
Abstract
Objective: We report the effects of several different measures of body size at baseline on the subsequent development of diabetes. High levels of body fat predict the onset of diabetes, but this association has not been previously reported in a large multiethnic population of overweight or obese people with impaired glucose tolerance.
Research methods and procedures: Height, weight, waist circumference, hip circumference, and skinfolds were measured at baseline in 3234 participants enrolled in a randomized clinical trial to treat individuals with impaired glucose tolerance with placebo, metformin, or a lifestyle modification program. Cox proportional hazards models were used to assess the effect of baseline body size variables on the development of diabetes.
Results: Over an average of 3.2 years in both the placebo and lifestyle groups, baseline waist circumference had the highest or second highest R(2) value for predicting diabetes in both sexes. Cox hazard ratios per 1 standard deviation were 1.43 and 1.49 for men in the placebo or lifestyle groups, respectively, and 1.29 and 1.53 for women in the placebo and lifestyle groups, respectively, adjusted for age and self-reported race/ethnicity. The c-statistic from the receiver operating characteristic curves also favored the waist circumference in men and women in the lifestyle group and men in the placebo group. No components of body size were predictive in the metformin-treated group, and metformin compared with the placebo group was effective in preventing diabetes only in individuals with a BMI > or =35 kg/m(2) or a waist circumference > or =98.0 cm.
Discussion: Large waist circumference was a better predictor of risk for developing diabetes than most other measures in the placebo and lifestyle groups. No baseline measure of body size or shape predicted risk of diabetes in the metformin-treated group.
Figures
Figure 1
Incidence of diabetes by waist circumference and treatment group in men (A) and women (B). Lifestyle lowered the incidence of diabetes similarly in all three tertiles of waist circumference. The incidence of diabetes was similar with metformin at all three levels of waist circumference. In men, the largest effect, relative to placebo, was seen in the group with the largest waist circumferences. In women, in those with the largest waist circumference, the effect of metformin was similar to that of lifestyle on the incidence of diabetes.
Figure 2
Incidence of diabetes by BMI and treatment group in men (A) and women (B). Lifestyle lowered the incidence rate at all three levels of BMI relative to placebo. In men, metformin was most effective in the highest BMI group, where the effect was similar to that of lifestyle. In women, metformin was effective only in the highest BMI group, where the effect was similar to that of lifestyle.
Similar articles
- Relation of central adiposity and body mass index to the development of diabetes in the Diabetes Prevention Program.
Bray GA, Jablonski KA, Fujimoto WY, Barrett-Connor E, Haffner S, Hanson RL, Hill JO, Hubbard V, Kriska A, Stamm E, Pi-Sunyer FX; Diabetes Prevention Program Research Group. Bray GA, et al. Am J Clin Nutr. 2008 May;87(5):1212-8. doi: 10.1093/ajcn/87.5.1212. Am J Clin Nutr. 2008. PMID: 18469241 Free PMC article. Clinical Trial. - Body size and shape changes and the risk of diabetes in the diabetes prevention program.
Fujimoto WY, Jablonski KA, Bray GA, Kriska A, Barrett-Connor E, Haffner S, Hanson R, Hill JO, Hubbard V, Stamm E, Pi-Sunyer FX; Diabetes Prevention Program Research Group. Fujimoto WY, et al. Diabetes. 2007 Jun;56(6):1680-5. doi: 10.2337/db07-0009. Epub 2007 Mar 15. Diabetes. 2007. PMID: 17363740 Free PMC article. Clinical Trial. - Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance.
Florez H, Temprosa MG, Orchard TJ, Mather KJ, Marcovina SM, Barrett-Connor E, Horton E, Saudek C, Pi-Sunyer XF, Ratner RE, Goldberg RB; Diabetes Prevention Program Research Group. Florez H, et al. Diabetes Obes Metab. 2014 Apr;16(4):326-33. doi: 10.1111/dom.12220. Epub 2013 Oct 29. Diabetes Obes Metab. 2014. PMID: 24118860 Free PMC article. Clinical Trial. - Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes.
Dodd JM, Grivell RM, Deussen AR, Hague WM. Dodd JM, et al. Cochrane Database Syst Rev. 2018 Jul 24;7(7):CD010564. doi: 10.1002/14651858.CD010564.pub2. Cochrane Database Syst Rev. 2018. PMID: 30039871 Free PMC article. Review.
Cited by
- Review of Metformin Use for Type 2 Diabetes Prevention.
Moin T, Schmittdiel JA, Flory JH, Yeh J, Karter AJ, Kruge LE, Schillinger D, Mangione CM, Herman WH, Walker EA. Moin T, et al. Am J Prev Med. 2018 Oct;55(4):565-574. doi: 10.1016/j.amepre.2018.04.038. Epub 2018 Aug 17. Am J Prev Med. 2018. PMID: 30126667 Free PMC article. Review. - Identifying obesity indicators which best correlate with type 2 diabetes in a Chinese population.
Xin Z, Liu C, Niu WY, Feng JP, Zhao L, Ma YH, Hua L, Yang JK. Xin Z, et al. BMC Public Health. 2012 Sep 1;12:732. doi: 10.1186/1471-2458-12-732. BMC Public Health. 2012. PMID: 22937748 Free PMC article. - TAS1R3 and TAS2R38 Polymorphisms Affect Sweet Taste Perception: An Observational Study on Healthy and Obese Subjects.
Cecati M, Vignini A, Borroni F, Pugnaloni S, Alia S, Sabbatinelli J, Nicolai G, Taus M, Santarelli A, Fabri M, Mazzanti L, Emanuelli M. Cecati M, et al. Nutrients. 2022 Apr 20;14(9):1711. doi: 10.3390/nu14091711. Nutrients. 2022. PMID: 35565677 Free PMC article. - Liver ATP synthesis is lower and relates to insulin sensitivity in patients with type 2 diabetes.
Schmid AI, Szendroedi J, Chmelik M, Krssák M, Moser E, Roden M. Schmid AI, et al. Diabetes Care. 2011 Feb;34(2):448-53. doi: 10.2337/dc10-1076. Epub 2011 Jan 7. Diabetes Care. 2011. PMID: 21216854 Free PMC article. - Prevention of Diabetes Through the Lifestyle Intervention: Lessons Learned from the Diabetes Prevention Program and Outcomes Study and its Translation to Practice.
Hoskin MA, Bray GA, Hattaway K, Khare-Ranade PA, Pomeroy J, Semler LN, Weinzierl VA, Wylie-Rosett J; for the Diabetes Prevention Program Research Group. Hoskin MA, et al. Curr Nutr Rep. 2014 Dec 1;3(4):364-378. doi: 10.1007/s13668-014-0094-2. Curr Nutr Rep. 2014. PMID: 25383256 Free PMC article.
References
- Knowler WC, Pettitt DJ, Savage PJ, Bennett PH. Diabetes incidence in Pima Indians: contributions of obesity and parental diabetes. Am J Epidemiol. 1981;113:144–56. - PubMed
- Larsson B, Björntorp P, Tibblin G. The health consequences of moderate obesity. Int J Obes. 1981;5:97–116. - PubMed
- Holbrook TL, Barrett-Connor E, Wingard DL. The association of lifetime weight and weight control patterns with diabetes among men and women in an adult community. Int J Obes. 1989;13:723–9. - PubMed
- Colditz GA, Willett WC, Stampfer MJ, et al. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol. 1990;132:501–13. - PubMed
- Colditz GA, Willet WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995;122:481–6. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical